Effects of DHA in Patients With Multiple Sclerosis

Condition(s) studied

Investigational drug(s) / intervention(s)

Docosahexaenoic Acid (DHA) Dietary Supplement: Subjects will take 2 g of DHA per day for 3 months.

Docosahexaenoic Acid (DHA) Dietary Supplement: Subjects will take 2 g of DHA per day + therapeutic exercise (3 times a week) for 3 months.

Sunflower Oil: Subjects will take 2 g of placebo (sunflower oil) per day for 3 months.

Sunflower Oil: Subjects will take 2 g of placebo per day + therapeutic exercise (3 times a week) for 3 months.

Study summary

This clinical trial will investigate the effects of combining therapeutic exercise with DHA supplementation in 100 patients with multiple sclerosis using a randomized controlled design. Participants, diagnosed according to the McDonald criteria, will undergo functional, cognitive, fatigue, and quality-of-life assessments through tools such as the EDSS, BRB-N, MFIS, EVA-f, and MSQoL-54. Physiological evaluations will include infrared thermography, isokinetic strength testing, perceived exertion (Modified Borg Scale), balance (Timed Up and Go), lower-limb power (Sit-to-Stand app), and handgrip strength. The study hypothesizes that this combined intervention will improve motor function, cognition, fatigue management, and overall quality of life by enhancing neuromuscular activation and metabolic efficiency.

Eligibility

Primary outcome measure(s)

• ISOKINETIC — Throughout study completion, an average of 12 weeks
  Measurement of isokinetic strength in the right leg N/m

Trial sites (1)

More Francisco Javier Martínez Noguera trials in Spain

Other trials for the same condition